Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06557356 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3532226 in Participants With Obesity
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 132
- Enrollment target
NCT06557356 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 132 participants.
The verdict
NCT06557356, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 132 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3532226 in participants with obesity. Blood tests will be performed to check how much LY3532226 gets into the bloodstream and how long it takes the body to eliminate it following weekly or monthly administration. Part A of the study will last approximately 16 weeks, excluding screening period. Part B of the study will last approximately 20 weeks, excluding the screening period. Part C of the study will last approximately 8 weeks, excluding the screening period.
Interventions
- DRUG Placebo
- DRUG LY3532226
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2024-08-16 |
| Est. Completion | 2025-12-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06557356
The ClinicalTrials.gov registry entry for NCT06557356 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06557356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06557356 about?
NCT06557356 is a clinical study titled "A Study of LY3532226 in Participants With Obesity". The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3532226 in participants with obesity. Blood tests will be performed to check how much LY3532226 gets into the bloodstream and how long it takes the body to eliminate it following weekly or monthly ...
What is the current status of trial NCT06557356?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 132 participants. The study started on 2024-08-16. Estimated completion is 2025-12-12.
What interventions are being tested in trial NCT06557356?
The interventions under investigation include: Placebo (DRUG), LY3532226 (DRUG).
Who is sponsoring clinical trial NCT06557356?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.